'Skinny' generic Vascepa label case reaches US Supreme Court SCOTUS has agreed to hear a patent dispute between Amarin and Hikma that could have implications for 'skinny labels' used by generic manufacturers.

The Supreme Court of the US (#SCOTUS) has agreed to hear a #patentdispute between #Amarin and #Hikma that could have implications for the legality of '#skinnylabels,' which can help #generic drugmakers bypass #intellectualproperty protections.

pharmaphorum.com/news/skinny-...

Supreme Court agrees to review 'skinny labeling' and generic drug access The Supreme Court agreed to review a controversy over so-called skinny labels for medicines, a decision that will be closely watched for its implications for the availability of generic medicines.

Supreme Court agrees to review ‘skinny labeling’ and generic drug access.. statnews.com/pharmalot/20... #pharma #SCOTUS #patents #generics #SupremeCourt #skinny #Amarin #Hikma

Image from image_1.jpg

The Hikma Club triumphed over Homentmen 131-120 in a tense match of the Décathlon Lebanese Basketball Championship, showcasing the sport's competitive spirit and rising popularity in Lebanon.

#LebanonBasketball #Hikma #LebaneseChampionship

Meine Jida sagte an Tagen wie diesem, wenn es regnete: Ya rouhi, das Wasser fällt vom Himmel, weil die Erde weint über das, was die Menschen vergessen haben. Damals klang es wie ein Rätsel. Heute weiß ich: Manche Wahrheiten brauchen Jahre – wie guter Tee oder alte Wunden. #Hikma

Generic drugmaker Hikma pledges $1bn in US investment With tariffs looming, Indian drugmaker Hikma has said it will spend $1bn to expand its manufacturing and R&D operations in the US by 2030.

Faced with the prospect of #tariffs on imported #medicines threatened by the #Trump administration, Indian drugmaker #Hikma has said it will spend $1 billion to expand its manufacturing and R&D operations in the #US by 2030.

pharmaphorum.com/news/generic...

AAPI : Le groupe pharmaceutique jordanien Hikma discute de ses projets en Algérie L'Agence algérienne de promotion de l'investissement (AAPI) a reçu une délégation du groupe pharmaceutique jordanien Hikma pour discuter de ses

Le groupe pharmaceutique jordanien #Hikma renforce sa présence en #Algérie avec une nouvelle unité de production et un projet d’extension dans les anticancéreux.

🔗 Lien de l’article : ecotimesdz.com/aapi-le-grou...

#Investissement #IndustriePharmaceutique #AAPI #ProductionLocale

Hikma shares edge up on steady guidance Investing.com -- Shares of Hikma Pharmaceuticals (OTC:HKMPY) PLC (LON:HIK) ticked up 0.6% on Thursday following the release of the company’s first quarter trading update for the fiscal year 2025. The pharmaceutical company reaffirmed its full-year guidance across all business segments, indicating that operations are progressing as planned. In its first quarter update, Hikma reported robust performance in its global Injectables business, particularly in European and Middle Eastern markets, and noted strong demand for the liraglutide injection and Xellia portfolio in North America. The company anticipates an uptick in momentum in the second half of 2025 with upcoming product launches and increased contract manufacturing. The expansion of the Bedford, Ohio facility is set to significantly enhance the company’s manufacturing capacity in the United States. The Generics segment is experiencing strong demand, especially for nasal and inhalation products. Hikma’s focus on supply reliability and high service levels, coupled with the use of its US manufacturing facility, is securing long-term customer contracts. The company is also investing in research and development, with progress being made at the new R&D center in Zagreb, Croatia, and preparations for a new contract manufacturing partnership at the Columbus (WA:CLC) facility moving forward. In the Branded segment, Hikma continues to perform well, with an emphasis on oncology and lifestyle diseases. The company has recently signed an exclusive licensing agreement to commercialize rucaparib, an oral oncology therapy, in the MENA region, which aligns with its strategy to be a leader in oncology medicines. Hikma also highlighted its expanding U.S. manufacturing footprint, which is a key supplier for its U.S. sales, and the maintenance of a diversified global supply chain for raw and packaging materials, including active pharmaceutical ingredients (APIs). For the fiscal year 2025, Hikma has reiterated its guidance, expecting group revenue to grow between 4% and 6%, with core operating profit projected to be in the range of $730 million to $770 million. Despite the overall positive trading update, Hikma noted that sales mix and phasing will impact margins in the first half of the year.

Click Subscribe #Hikma #StockMarket #Investing #Stocks #Finance

Hikma Pharmaceuticals Partners with Emergent BioSolutions for KLOXXADO® Naloxone Nasal Spray Distribution Hikma Pharmaceuticals has entered into an exclusive agreement with Emergent BioSolutions to market KLOXXADO® naloxone nasal spray, enhancing access to opioid overdose treatment in North America.

Hikma Pharmaceuticals Partners with Emergent BioSolutions for KLOXXADO® Naloxone Nasal Spray Distribution #London #United_Kingdom #Hikma #KLOXXADO #Emergent_BioSolutions

Weekly Roundup - PHARMA - 6 January 2025 🔊BMS's Opdivo Qvantig FDA-Approved for Subcutaneous Use in NSCLC and Solid Tumors Bristol Myers Squibb's Opdivo Qvantig receives FDA approval for subcutaneous use in NSCLC and other solid tumors. The ...

Weekly Roundup - PHARMA - 6 January 2025

www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#FDA #Hikma #GLP1 #Victoza #EliLilly #Zepbound #ObesityTreatment #RhythmPharma #Setmelanotide #Imcivree #GeneticObesity #Pfizer #Braftovi #Humanteconomy #Humantec #KStrategyand

Weekly Roundup - PHARMA - 30 December 2024 🔊FDA Approves Hikma's First Generic GLP-1 Injection for Type 2 Diabetes The FDA has approved the first generic daily GLP-1 injection for type 2 diabetes, referencing Novo Nordisk’s Victoza. The approv...

Weekly Roundup - PHARMA - 30 December 2024

Click here to read more ➡ www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#FDA #Hikma #GLP1 #Victoza #EliLilly #Zepbound #ObesityTreatment #RhythmPharma #Setmelanotide #Imcivree #Humanteconomy #Humantec #KStrategyand

Muhsin Fayd Kashani was one of the leading scholars of the #Safavid period in #hadith #philosophy #hikma #Quranic_exegesis and a translation of his Al-Asfa has just appeared with #ICAS_Press in London

Federal Circuit reverses dismissal in Amarin v. Hikma, a significant case on skinny-label generics and induced infringement. The ruling emphasizes the impact of marketing and public statements on inducement claims. #Amarin #Hikma #Generics #PatentInfring… https://buff.ly/4eFOBzM